Boston Therapeutics, Inc.
354 Merrimack Street Suite 4
Lawrence, Massachusetts 01843
The company was formerly known as Avanyx Therapeutics, Inc. and went public through a reverse merger in 2009. The Company changed its name to Boston Therapeutics, Inc. in November 2010.
Boston Therapeutics is an early development stage biopharmaceutical company that focuses on becoming a leader in the area of complex carbohydrate therapy. Their research efforts are dedicated towards developing patented therapeutic solutions for the management and prevention of diabetes.
BTI320 and Sugardown are non-systemic, non-toxic, chewable formulations that have been shown clinically to reduce post-meal glucose spikes. These compounds are based on medical research of the role of carbohydrate molecules and are thought to play an important role in many diseases such as cancer, cardiovascular disease, Alzheimer’s and inflammatory diseases.
COMPANY BUSINESS SUMMARY
Boston Therapeutic, Inc. believes that they are the pioneer in the development of new carbohydrate-based therapeutics and dietary supplements for regulation of post meal glucose excursion and management of healthy blood sugar levels. The Company is advancing BTI320 through regulatory body approval in the US, Asia and the EU. They expect to commercialize either de novo or in a partnership with successful regulatory approvals in these regions.
The Company currently sells Sugardown, which is developed based on BTI320, as an over the counter dietary supplement to regulate glucose metabolism by reducing post meal glucose elevation. Its mechanism of action is triggered in the gastrointestinal tract by blocking the enzymes that block some of the glucose released during digestion of carbohydrate foods. Early Ph 1 studies demonstrated that Sugardown is effective in maintaining healthy post meal blood sugar levels.
Boston Therapeutics, Inc. is targeting the diabetes market because of its critical mass and believes that success with on-going research and development would lead to a possible partnership to penetrate the Type II diabetes market and capture market share.
With operations in both the US and Hong Kong, the Company is leveraging on the strengths of both countries. The Company plans to ramp up worldwide sales and distribution of Sugardown by leveraging the significant clinical studies that have been completed, and capitalizing on the strong patent position of this unique dietary supplement formulation.
SHARE RELATED INFORMATION
|52 Week High:||.115 on 2/20/18||Total Shares Outstanding:||110,131,373|
|52 Week Low:||.013 on 11/1/18||Public Float:||60,000,000|
|All time High:||$1.65 on 1/1/14||Earnings Per Share:|
|All time Low:||.013 on 11/1/18||Book Value:|
View Historical Stock Prices & Volume for this company
FUNDAMENTAL INVESTMENT HIGHLIGHTS
All numbers in Thousands
Prior Fiscal Yr
|Pre-Tax Earnings (Losses)||($1,585)||($3,773)||$764|
View all Filings for this company
NEWSPAPER / MAGAZINE ARTICLES / RESEARCH REPORTS
Click here to go Back